RIGEL PHARMACEUTICALS INC — Earnings

Most recent reported period: FY2026 (Q1) (filed for period ending 2026-03-31) · sourced from SEC EDGAR

Next earnings (estimated): Tue, June 30, 2026 ~53 days away. Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)

Recent earnings · last 8 quarters

Quarter endRevenueYoYNet IncomeYoYOp. Margin
2026-03-31$59M↑+10.3%$9M↓-24.4%20.2%
2025-12-31$70M↑+21.2%$268M↑+5193.5%33.2%
2025-09-30$69M↑+25.6%$28M↑+124.6%40.9%
2025-06-30$102M↑+176.0%$60M↑+5887.7%60.1%
2025-03-31$53M↑+80.6%$11M↑+238.8%23.9%
2024-12-31$58M↑+60.9%$5M↑+587.1%17.6%
2024-09-30$55M↑+96.6%$12M↑+318.2%25.4%
2024-06-30$37M↑+37.0%$-1M↑+84.4%1.2%

Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.

Last earnings · FY2026 (Q1)

Revenue
$59M
↑+10.3% +$5M YoY
Net Income
$9M
↓-24.4% -$3M YoY

Earnings surprise · last 8 quarters

YoY % change · proxy for analyst surprise until estimates land

EPS history · last 10 fiscal years

diluted, GAAP, annual

Note: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.

Margin trends · 64 quarters

margin trajectory tells the operating-leverage story
Gross Margin↑+5.8pts
94.5%
Operating Margin↓-3.7pts
20.2%
Net Margin↓-6.7pts
14.7%

Go deeper